- Target disease: Visceral Leishmaniasis
- Main Partners (since project start): Celgene Global Health, USA; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene & Tropical Medicine, UK; Sandexis, UK; WuXi AppTech, China.
- Project start: 2015
- Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), the Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International.
A novel series of heterocyclic compounds for VL has been optimized by Celgene in collaboration with London School of Hygiene & Tropical Medicine and Advinus, and with advice from DNDi.
An in vivo proof-of-concept has been achieved for this series. An intensive lead optimization programme is ongoing with Celgene to identify an optimized lead.
Last update: August 2017